Risedronate rapidly reduces vertebral fracture risk in postmenopausal women with established osteoporosis

被引：0
|
作者：
Roux, C
Miller, P
Gennari, C
Keller, M
Sorensen, O
Ritter-Hrncirik, C
Barton, I
Watts, N
机构：
来源：
ARTHRITIS AND RHEUMATISM | 1999年 / 42卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1300
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [31] Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
    Palacios, S.
    Kalouche-Khalil, L.
    Rizzoli, R.
    Zapalowski, C.
    Resch, H.
    Adachi, J. D.
    Gallagher, J. C.
    Feldman, R. G.
    Kendler, D. L.
    Wang, A.
    Wagman, R. B.
    Adami, S.
    CLIMACTERIC, 2015, 18 (06) : 805 - 812
  • [32] Strontium ranelate reduces the risk of non vertebral fractures in women with postmenopausal osteoporosis
    Reginster, JY
    Lorenc, RS
    Spector, TD
    Benhamou, C
    Isaia, G
    Brixen, K
    Stucki, G
    Prins, J
    Walravens, M
    Cannata, JB
    De Chatel, R
    Meunier, PJ
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S51 - S52
  • [33] Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis
    Reginster, JY
    Sawicki, A
    Devogelaer, JP
    Padrino, JM
    Kaufma, JM
    Doyle, DV
    Fardellone, P
    Graham, J
    Felsenberg, D
    Tulassay, Z
    Soren-Sen, OH
    Luisetto, G
    Rizzoli, R
    Blotman, F
    Phenekos, C
    Meunier, PJ
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S14 - S14
  • [34] Risedronate rapidly and consistently reduces risk of vertebral fracture in patients with varying degrees of osteoporotic severity.
    Cohen, S
    Roux, C
    Eastell, R
    Mulder, H
    Harris, ST
    Pack, S
    Watts, NB
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S197 - S197
  • [35] Rapid and consistent effect of risedronate on vertebral fracture risk reduction in elderly postmenopausal women.
    Greenwald, M
    Fischer, M
    Poiley, J
    Bos, K
    Reginster, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S226 - S226
  • [36] Safety and efficacy of risedronate in reducing vertebral fracture risk in elderly women with documented osteoporosis.
    Boonen, S
    Eastell, R
    Barton, IP
    McClung, MR
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S370 - S370
  • [37] Risedronate reduces the risk of clinical vertebral fractures as early as 6 months and non-vertebral fractures as early as 12 months in women with postmenopausal osteoporosis.
    Bolognese, M
    Chesnut, C
    Adami, S
    Barton, I
    Watts, N
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S254 - S254
  • [38] Effects of risedronate on fracture risk in postmenopausal women with osteopenia
    E. S. Siris
    J. A. Simon
    I. P. Barton
    M. R. McClung
    A. Grauer
    Osteoporosis International, 2008, 19 : 681 - 686
  • [39] Effects of risedronate on fracture risk in postmenopausal women with osteopenia
    Siris, E. S.
    Simon, J. A.
    Barton, I. P.
    McClung, M. R.
    Grauer, A.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (05) : 681 - 686
  • [40] Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with postmenopausal osteoporosis
    Adami, S
    Meunier, PJ
    Devogelaer, JP
    Hoszowski, K
    Fardellone, P
    Benhamou, V
    Brixen, K
    Bonidan, O
    Marcelli, C
    Reginster, JY
    Fechtenbaum, J
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S93 - S94
12345